Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Digital transformation in pharma is not ... in order to make sure the products being developed are effective and easy to use. One example of a patient-facing app in Biogen’s portfolio is Cleo ...

While there are RNAi products on the marketplace ... different strategic collaborations with its big pharma backers. The partnership with Biogen will develop RNAi therapeutics for multiple ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...

SAN FRANCISCO Jan 14 (Reuters) - Biogen (BIIB.O), opens new tab expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business ...

Shares of Biogen Inc. BIIB slid 1.10% to $142.34 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 and Dow ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for Alzheimer’s disease, providing a response after a meeting next month.

The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics Inc. is looking for a deal — but it’s ...